Acute lymphoid leukemia (ALL)
Immunotherapy with daratumumab safe and active in relapsed ALL and LL (Bhatla et al., 2024) Immunotherapy with daratumumab is safe for children with relapsed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) in whom standard chemotherapy fails.
Liso-cel offers no improvement in children with relapsed leukemia (2024) Treatment with liso-cel, a form of CAR T-cell therapy, did not work well enough in children with relapsed leukemia.
Leukemia drug keeps working in continuous treatment schedule (Van der Sluis et al., 2024) Researchers have found a better way to give an important drug in the treatment of leukemia, PEGasparaginase.
Survival of aggressive T-cell leukemia nearly doubled (Raetz et al., 2023) The survival of children with an aggressive form of T-cell leukemia has almost doubled, from 28% to 55%.
Immunotherapy strongly improves prognosis of babies with leukemia (Van der Sluis et al., 2023) Immunotherapy treatment is safe and effective for babies with leukemia, according to results of a clinical trial led by researchers from the Princess Máxima Center.
Extending chemo slashes risk of aggressive childhood leukemia coming back (Pieters et al, 2022) In the ALL-11 treatment protocol the benefit of an adapted treatment in specific groups of children with leukemia was evaluated.
Detailed analysis of a high-risk form of ALL (Den Boer et al, 2021) Children with rare aberrations in genes of the so-called ABL-class have a higher risk of recurrence.
Inotuzumab ozogamicin in relapsed or refractory ALL (Brivio et al., 2020) A new drug shows promising activity in an early-phase study in a small number of children.
Acute myeloid leukemia (AML)
Effective treatment options for relapsing AML (White et al., 2022) Third-line treatment offers a modest, but real chance of a cure for children with refractory first relapse or second relapse Acute Myeloid Leukemia (AML).
ACCELERATE: stimulating the development of medicinal products for children with AML (Pearson et al., 2020) Novel anticancer agents that have been developed for adults are not always suitable for use in children, although new medicines are urgently needed.
Survival rate of children with acute myeloid leukemia nearly doubles (Reedijk et al., 2019) In a new study, researchers at the Princess Máxima Center found that survival rates in the Netherlands have nearly doubled over recent decades.
FLT3 inhibitors in the treatment of AML (Zwaan et al., 2018) Mutations in the FLT3-gene confer a poor prognosis in children with AML. Targeted inhibition of FLT3 may be a promising strategy for treatment.
Can progression from transient myeloid disease to AML be prevented in children with Down syndrome ? (Flasinski et al., 2018) Treatment with low-dose cytarabine prevents early death from leukemia.
Clofarabine, cytarabine and liposomal daunorubicin for relapsed AML (Van Eijkelenburg et al., 2018) A new combination of chemotherapeutic agents was well tolerated and showed high response rates.
Chronic myeloid leukemia (CML)
Chronic myeloid leukemia drug approved in the US (Brivio et al, 2024) The FDA (Food and Drug Administration) has approved a new medicine for children with chronic myeloid leukemia (CML) based on research conducted by the team of Prof. Michel Zwaan.
Dasatinib is safe and active in pediatric CML (Gore et al., 2018) Children who received the drug dasatinib achieved rapid and deep responses, also those who were resistant or intolerant to the drug imatinib.
Juvenile myelomonocytic leukemia (JMML)
Drug azacitidine safe for children with relapsed MDS or JMML (Rubio-San-Simón A, et al., 2023) Azacitidine can be safely given to children with myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) in whom the disease has recurred. Particularly for JMML, it also seems to work well.